These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 36137077)

  • 21. Association between inappropriate empirical antimicrobial therapy and hospital length of stay in Gram-negative bloodstream infections: stratification by prognosis.
    Battle SE; Bookstaver PB; Justo JA; Kohn J; Albrecht H; Al-Hasan MN
    J Antimicrob Chemother; 2017 Jan; 72(1):299-304. PubMed ID: 27986899
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Increased Costs Associated with Bloodstream Infections Caused by Multidrug-Resistant Gram-Negative Bacteria Are Due Primarily to Patients with Hospital-Acquired Infections.
    Thaden JT; Li Y; Ruffin F; Maskarinec SA; Hill-Rorie JM; Wanda LC; Reed SD; Fowler VG
    Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 27993852
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oral antibiotics for the treatment of Gram-negative bloodstream infections: A retrospective comparison of three antibiotic classes.
    Nisly SA; McClain DL; Fillius AG; Davis KA
    J Glob Antimicrob Resist; 2020 Mar; 20():74-77. PubMed ID: 31390537
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of Short Versus Long Courses of Antibiotics in Critically Ill Patients With Gram-Negative Bloodstream Infections.
    Anderson DT; Sharma D; Chase AM; Sulaiman ZI; Anderson AH; Huggett AL; Eudy J
    Ann Pharmacother; 2024 Nov; 58(11):1081-1088. PubMed ID: 38347703
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combination therapy vs. monotherapy for Gram-negative bloodstream infection: matching by predicted prognosis.
    Justo JA; Bookstaver PB; Kohn J; Albrecht H; Al-Hasan MN
    Int J Antimicrob Agents; 2018 Mar; 51(3):488-492. PubMed ID: 28919195
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development of a bedside tool to predict the probability of drug-resistant pathogens among hospitalized adult patients with gram-negative infections.
    Lodise TP; Bonine NG; Ye JM; Folse HJ; Gillard P
    BMC Infect Dis; 2019 Aug; 19(1):718. PubMed ID: 31412809
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Incidence and predictors of complications in Gram-negative bloodstream infection.
    Mondal U; Warren E; Bookstaver PB; Kohn J; Al-Hasan MN
    Infection; 2024 Oct; 52(5):1725-1731. PubMed ID: 38436912
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Third generation cephalosporin resistant Enterobacteriaceae and multidrug resistant gram-negative bacteria causing bacteremia in febrile neutropenia adult cancer patients in Lebanon, broad spectrum antibiotics use as a major risk factor, and correlation with poor prognosis.
    Moghnieh R; Estaitieh N; Mugharbil A; Jisr T; Abdallah DI; Ziade F; Sinno L; Ibrahim A
    Front Cell Infect Microbiol; 2015; 5():11. PubMed ID: 25729741
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diagnostic and Therapeutic Yield of Imaging Studies in Patients with Dementia and Gram-negative Bloodstream Infections: A Retrospective Cohort Study.
    Massalha M; Reisfeld S
    Isr Med Assoc J; 2024 Jun; 26(6):383-387. PubMed ID: 38884312
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Which trial do we need? Early oral antibiotic therapy for the treatment of gram-negative bloodstream infections.
    Tamma PD; Cosgrove SE
    Clin Microbiol Infect; 2023 Jun; 29(6):670-672. PubMed ID: 36805881
    [No Abstract]   [Full Text] [Related]  

  • 31. Association of 30-Day Mortality With Oral Step-Down vs Continued Intravenous Therapy in Patients Hospitalized With Enterobacteriaceae Bacteremia.
    Tamma PD; Conley AT; Cosgrove SE; Harris AD; Lautenbach E; Amoah J; Avdic E; Tolomeo P; Wise J; Subudhi S; Han JH;
    JAMA Intern Med; 2019 Mar; 179(3):316-323. PubMed ID: 30667477
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oral antibiotic step-down therapy for nonstaphylococcal gram-positive bloodstream infections.
    Gandhi K; Wrzesinski M; Bunnell K; Gibble A
    Diagn Microbiol Infect Dis; 2023 Dec; 107(4):116068. PubMed ID: 37774630
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative-Effectiveness of Oral Beta-Lactams and Fluoroquinolones for Stepdown Therapy in Patients with Enterobacterales Bloodstream Infections: A Retrospective Cohort Study.
    Bjork L; Hopkins T; Yang L; Teng C; Jones X; Cadena J; Walter E; Frei CR
    Int J Med Sci; 2023; 20(4):437-443. PubMed ID: 37057217
    [No Abstract]   [Full Text] [Related]  

  • 34. Impact of multiresistance of gram-negative bacteria in bloodstream infection on mortality rates and length of stay.
    Sostarich AM; Zolldann D; Haefner H; Luetticken R; Schulze-Roebecke R; Lemmen SW
    Infection; 2008 Feb; 36(1):31-5. PubMed ID: 18231721
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antibiotic-resistant Gram-negative bacteremia in pediatric oncology patients--risk factors and outcomes.
    Haeusler GM; Mechinaud F; Daley AJ; Starr M; Shann F; Connell TG; Bryant PA; Donath S; Curtis N
    Pediatr Infect Dis J; 2013 Jul; 32(7):723-6. PubMed ID: 23838774
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Follow-up blood culture in Gram-negative bacilli bacteraemia: for whom is follow-up blood culture useful?
    Giannella M; Pascale R; Viale P
    Curr Opin Infect Dis; 2022 Dec; 35(6):552-560. PubMed ID: 35942855
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rapid testing using the Verigene Gram-negative blood culture nucleic acid test in combination with antimicrobial stewardship intervention against Gram-negative bacteremia.
    Bork JT; Leekha S; Heil EL; Zhao L; Badamas R; Johnson JK
    Antimicrob Agents Chemother; 2015 Mar; 59(3):1588-95. PubMed ID: 25547353
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prediction of Fluoroquinolone Resistance in Gram-Negative Bacteria Causing Bloodstream Infections.
    Dan S; Shah A; Justo JA; Bookstaver PB; Kohn J; Albrecht H; Al-Hasan MN
    Antimicrob Agents Chemother; 2016 Apr; 60(4):2265-72. PubMed ID: 26833166
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of fluoroquinolone resistance in Gram-negative bloodstream infections on healthcare utilization.
    Brigmon MM; Bookstaver PB; Kohn J; Albrecht H; Al-Hasan MN
    Clin Microbiol Infect; 2015 Sep; 21(9):843-9. PubMed ID: 26003282
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Short-course aminoglycosides as adjunctive empirical therapy in patients with Gram-negative bloodstream infection, a cohort study.
    Deelen JWT; Rottier WC; Buiting AGM; Dorigo-Zetsma JW; Kluytmans JAJW; van der Linden PD; Thijsen SFT; Vlaminckx BJM; Weersink AJL; Ammerlaan HSM; Bonten MJM; van Werkhoven CH
    Clin Microbiol Infect; 2021 Feb; 27(2):269-275. PubMed ID: 32387438
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.